NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

$33.63

-0.37 (-1.09%)

(As of 09:39 AM ET)

Compare

Today's Range: $33.63
▼
$34.94
50-Day Range: $28.53
▼
$39.55
52-Week Range: $11.07
▼
$47.25

Volume: 4,757 shs
Average Volume: 774,168 shs
Market Capitalization: $1.96 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.40

Ventyx Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 64.7% Upside
$55.40 Price Target
Short Interest: Bearish
19.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.10
Based on 2 Articles This Week
Insider Trading: Selling Shares
$15.80 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.76) to ($3.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

668th out of 980 stocks

Pharmaceutical Preparations Industry

333rd out of 485 stocks

3.5

Analyst's Opinion

Consensus Rating
Ventyx Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $55.40, Ventyx Biosciences has a forecasted upside of 64.7% from its current price of $33.63.
Amount of Analyst Coverage
Ventyx Biosciences has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
19.19% of the float of Ventyx Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Ventyx Biosciences has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in Ventyx Biosciences has recently increased by 6.17%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ventyx Biosciences does not currently pay a dividend.
Dividend Growth
Ventyx Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTYX.

1.2

News and Social Media Coverage

News Sentiment
Ventyx Biosciences has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Ventyx Biosciences this week, compared to 4 articles on an average week.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ventyx Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,802,931.00 in company stock.
Percentage Held by Insiders
24.39% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.57% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.76) to ($3.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ventyx Biosciences is -14.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ventyx Biosciences is -14.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ventyx Biosciences has a P/B Ratio of 5.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

VTYX Stock News Headlines

June 4, 2023 | americanbankingnews.com

William J. Sandborn Sells 10,629 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

May 25, 2023 | americanbankingnews.com

Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $55.40

June 5, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 18, 2023 | americanbankingnews.com

William J. Sandborn Sells 3,487 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

May 12, 2023 | markets.businessinsider.com

Ventyx Biosciences (VTYX) Gets a Buy from LifeSci Capital

May 12, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Ventyx Biosciences

May 12, 2023 | msn.com

Preview: Ventyx Biosciences's Earnings

May 12, 2023 | finance.yahoo.com

Q1 2023 Ventyx Biosciences Inc Earnings Call

June 5, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 12, 2023 | finanznachrichten.de

Ventyx Biosciences, Inc.: Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

May 12, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)

May 12, 2023 | markets.businessinsider.com

Ventyx Biosciences (VTYX) Receives a Buy from Goldman Sachs

May 11, 2023 | msn.com

Recap: Ventyx Biosciences Q1 Earnings

May 11, 2023 | finance.yahoo.com

Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

May 9, 2023 | americanbankingnews.com

Ventyx Biosciences (VTYX) Scheduled to Post Quarterly Earnings on Thursday

May 8, 2023 | americanbankingnews.com

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Sells 30,000 Shares

May 4, 2023 | finance.yahoo.com

Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023

May 4, 2023 | americanbankingnews.com

Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells 10,790 Shares of Stock

May 2, 2023 | americanbankingnews.com

Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Target Price at $55.40

May 2, 2023 | americanbankingnews.com

Financial Analysis: Ventyx Biosciences (VTYX) versus Its Peers

April 30, 2023 | americanbankingnews.com

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Sees Significant Decline in Short Interest

April 28, 2023 | americanbankingnews.com

Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Major Shareholder Sells 8,642 Shares of Stock

April 28, 2023 | americanbankingnews.com

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CFO Martin Auster Sells 28,000 Shares

April 28, 2023 | americanbankingnews.com

Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Major Shareholder Sells $3,499,431.60 in Stock

April 27, 2023 | americanbankingnews.com

Somu Subramaniam Sells 793 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

April 22, 2023 | americanbankingnews.com

Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) CFO Sells $231,000.00 in Stock

April 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Alphatec Holdings (ATEC), Ventyx Biosciences (VTYX)

See More Headlines

VTYX Price History

30 days | 90 days | 365 days | Advanced Chart

VTYX Company Calendar

Last Earnings: 3/23/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VTYX
CUSIP: N/A
CIK: 1851194
Web: www.ventyxbio.com
Phone: 760-593-4832
Fax: N/A
Employees: 27
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $55.40
High Stock Price Forecast: $77.00
Low Stock Price Forecast: $35.00
Forecasted Upside/Downside: +62.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -36.87%
Return on Assets: -34.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.44
Quick Ratio: 23.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.37 per share
Price / Book: 5.34

Miscellaneous

Outstanding Shares: 58,350,000
Free Float: 44,118,000
Market Cap: $1.98 billion
Optionable: Not Optionable
Beta: -0.36

Key Executives

Dr. Sheila K. Gujrathi M.D. (Age 53)
Exec. Chair
Comp: $81.14k

Dr. Raju S. Mohan Ph.D. (Age 65)
Founder, CEO & Director
Comp: $783.73k

Dr. John M. Nuss Ph.D. (Age 64)
Chief Scientific Officer
Comp: $5.57M

Mr. Christopher W. Krueger J.D. (Age 55)
MBA, Chief Bus. Officer
Comp: $568.14k

Prof. William J. Sandborn M.D.
Ph.D., Pres & Chief Medical Officer

Dr. Martin Douglas Auster M.D. (Age 48)
Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VTYX Stock - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VTYX shares.
View VTYX analyst ratings or view top-rated stocks.
What is Ventyx Biosciences' stock price forecast for 2023?: 8 analysts have issued twelve-month price objectives for Ventyx Biosciences' shares. Their VTYX share price forecasts range from $35.00 to $77.00. On average, they anticipate the company's stock price to reach $55.40 in the next year. This suggests a possible upside of 62.9% from the stock's current price.
View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts.
How have VTYX shares performed in 2023?: Ventyx Biosciences' stock was trading at $32.79 on January 1st, 2023. Since then, VTYX stock has increased by 3.7% and is now trading at $34.00.
View the best growth stocks for 2023 here.
When is Ventyx Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VTYX earnings forecast.
How were Ventyx Biosciences' earnings last quarter?: Ventyx Biosciences, Inc. (NASDAQ:VTYX) posted its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.03.
What ETFs hold Ventyx Biosciences' stock?: ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Alger Mid Cap 40 ETF (FRTY), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Nuveen Small Cap Select ETF (NSCS).

When did Ventyx Biosciences IPO?: (VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.
What is Ventyx Biosciences' stock symbol?: Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."
Who are Ventyx Biosciences' major shareholders?: Ventyx Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (13.35%), Price T Rowe Associates Inc. MD (4.71%), BlackRock Inc. (3.60%), RTW Investments LP (2.44%), Wellington Management Group LLP (1.53%) and Pictet Asset Management SA (1.31%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends.
How do I buy shares of Ventyx Biosciences?: Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ventyx Biosciences' stock price today?: One share of VTYX stock can currently be purchased for approximately $34.00.
How much money does Ventyx Biosciences make?: Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $1.98 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.
How can I contact Ventyx Biosciences?: The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com.

This page (NASDAQ:VTYX) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ventyx Biosciences (VTYX) Stock Forecast, Price & News

Ventyx Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Ventyx Biosciences (NASDAQ:VTYX) Stock

VTYX Stock News Headlines

VTYX Price History

VTYX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VTYX Stock - Frequently Asked Questions

Overall MarketRank^™